Related Experiment Video
Updated: Aug 23, 2026
Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
Published on: October 3, 2019
Genetic manipulation of myocardial beta-adrenergic receptor activation and desensitization
Jonathan A Hata1, Matthew L Williams, Walter J Koch
1Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
Insights
Heart failure involves altered beta-adrenergic receptor (beta AR) signaling, often due to increased G-protein-coupled receptor kinase 2 (GRK2). Targeting beta ARs and GRKs shows promise for new heart failure therapies.
Area of Science:
- Cardiology
- Molecular Biology
- Pharmacology
Background:
- Heart failure (HF) is a major cause of death, characterized by impaired beta-adrenergic receptor (beta AR) signaling in the heart.
- Beta ARs, crucial for cardiac function, become desensitized and downregulated in HF due to chronic sympathetic stimulation.
- G-protein-coupled receptor kinases (GRKs), particularly GRK2 (beta ARK1), play a key role in this desensitization process and are elevated in HF patients.
Purpose of the Study:
- To investigate the role of beta-adrenergic receptors (beta ARs) and G-protein-coupled receptor kinases (GRKs) in the pathogenesis of heart failure.
- To explore the therapeutic potential of targeting the beta AR signaling pathway in myocardial dysfunction.
Main Methods:
- Utilized transgenic mouse models to study the association between beta ARs, GRKs, and cardiac function.
- Investigated the impact of GRK2 (beta ARK1) levels on myocardial beta AR signaling.
- Employed gene therapy strategies to manipulate the beta AR signaling pathway in the heart.
Main Results:
- Demonstrated that GRK2 (beta ARK1) is significantly increased in human HF and plays a vital role in regulating myocardial beta AR signaling.
- Transgenic mouse models confirmed the critical role of beta ARK1 in the desensitization and downregulation of beta ARs.
- Gene therapy interventions targeting the beta AR signaling pathway led to improved cardiac function in compromised hearts.
Conclusions:
- Beta-adrenergic receptors and GRKs are implicated in the pathophysiology of heart failure.
- GRK2 (beta ARK1) is a key mediator of dysfunctional beta AR signaling in HF.
- Targeting beta ARs and GRKs, potentially through gene therapy, offers a promising therapeutic strategy for heart failure.
Abstract:
Heart failure (HF) represents one of the leading causes of morbidity and mortality in developed nations today. Although this disease process represents a final common endpoint for several entities, including hypertension, coronary artery disease, and cardiomyopathy, a predominant characteristic of end-stage HF is an altered beta-adrenergic receptor signaling cascade. In the heart, beta-adrenergic receptors (beta ARs), members of the superfamily of G-protein-coupled receptors (GPCRs), modulate cardiac function by controlling chronotropic, inotropic, and lusitropic responses to catecholamines of the sympathetic nervous system. In HF, beta ARs are desensitized and downregulated in a maladaptive response to chronic stimulation. This process is largely mediated by G-protein-coupled receptor kinases (GRKs), which phosphorylate GPCRs leading to functional uncoupling. The most abundant cardiac GRK, known as GRK2 or beta AR kinase 1 (beta ARK1), is increased in human HF, and has been implicated in the pathogenesis of dysfunctional cardiac beta AR signaling. The association of beta ARs and GRKs with impaired cardiac function has been extensively studied using transgenic mouse models, which have demonstrated that beta ARK1 plays a vital role in the regulation of myocardial beta AR signaling. These findings have caused beta ARs and GRKs to be regarded as potential therapeutic targets, and gene therapy strategies have been used to manipulate the beta AR signaling pathway in myocardium, leading to improved function in the compromised heart. Ultimately, these genetic modifications of the heart may represent new potential therapies for human HF.
More Related Videos
06:42A Simple and Efficient Method for In Vivo Cardiac-specific Gene Manipulation by Intramyocardial Injection in Mice
Published on: April 16, 2018
09:16Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
Published on: June 3, 2018
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
01:22Heart Failure Drugs: β-Blockers